World Precision Instruments (WPI), a global leader in transepithelial electrical resistance (TEER) instrumentation, and SynVivo Inc., a pioneer in Organ-on-a-Chip (OOC) technology, announced the commercial launch of a next-generation multiplexed TEER-on-a-Chip platform—a breakthrough solution enabling real-time, high-throughput measurement of barrier integrity in advanced Organ-on-a-Chip models.
Somnics Health, a pioneer in next-generation sleep apnea solutions, announces the launch of iNAP Essentials, a breakthrough program giving patients access to iNAP Sleep Therapy for just $58/month over 24 months. This new initiative removes one of the biggest barriers to treatment—cost—and expands access to comfortable, mask-free therapy for patients with Obstructive Sleep Apnea (OSA).
HistoSonics, the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, announced that Addenbrookes Hospital of Cambridge University Hospital Foundation and Trust will be the first site in the United Kingdom and European continent to offer histotripsy to both NHS and private patients. This was made possible through a generous donation by the Li Ka Shing Foundation (LKSF) as well as the expedited limited market access granted by the MHRA in April 2025.
ZAP Surgical Systems, Inc., a global leader in non-invasive robotic brain surgery, announced that its first ZAP-X® Gyroscopic Radiosurgery® platform will soon be installed in Mexico at the newly established Gray Medical Institute, located in San Pedro, part of the Monterrey Metropolitan area in the Mexican state of Nuevo León.
Hyperfine, Inc. the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—announced FDA clearance of its most significant technological advancement to date. The clearance includes an entirely new portable MRI scanner powered by the proprietary Optive AI™ software.
GE HealthCare announced that the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for clinicians now recommend considering fluoroestradiol (FES) positron emission tomography (PET) for systemic staging in patients with recurrent or metastatic lobular breast cancer.
Atia Vision, Inc., a Shifamed portfolio company, announced it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to begin a traditional feasibility clinical study of its OmniVu™ Lens System. This novel intraocular lens is designed to restore dynamic range of vision following cataract surgery, going beyond the capabilities of current presbyopia-correcting lenses.
Stryker a global leader in medical technologies, announced that its OptaBlate basivertebral nerve ablation system (OptaBlate BVN) received 510(k) clearance from the U.S. Food and Drug Administration. OptaBlate BVNA is used in a targeted minimally invasive procedure providing long-lasting† vertebrogenic pain relief1.
Boston Scientific Corporation announced positive 12-month primary endpoint results from the second phase of the ADVANTAGE AF clinical trial evaluating the use of the FARAPULSE™ Pulsed Field Ablation (PFA) System* and adjunctive use of the FARAPOINT™ PFA Catheter in patients with persistent atrial fibrillation (AF). Key findings from the study were presented at the second annual PFA Live Case Summit in San Diego and simultaneously published in Circulation.
SonoMotion, a medical device company developing noninvasive solutions for kidney stones, announced it has been awarded a $2.2 million NIH grant and successfully completed patient enrollment in the SOUND Break Wave pivotal clinical trial.